Literature DB >> 17690028

Regulating regulatory T cells to achieve transplant tolerance.

Ran Tao1, Wayne W Hancock.   

Abstract

BACKGROUND: Regulatory T cells (Tregs) play crucial roles in both induction and maintenance of tolerance. This active immune regulation may contribute not only to the control of immune responses to self-antigens and thereby prevent autoimmune diseases, but also the control of responses to non-self molecules in adaptive immunity. Numerous experimental and clinical studies indicate that manipulating the balance between regulatory and responder T cells is an effective strategy to control immune responsiveness after transplantation. DATA SOURCES: Literature search was conducted using PubMed on the related subjects. Part of the material was based on the most recent work in the authors' laboratory.
RESULTS: We propose some new strategies to achieve transplant tolerance in rodent animals via manipulating Treg function, including using histone deacetylase (HDAC) inhibitor to regulate Foxp3 transcription and enhance Treg suppression, induction of Treg-sparing apoptosis via Nur77, and identification of the co-inhibitory molecule herpes virus entry mediator (HVEM) as an effector molecule for Treg function.
CONCLUSION: Regulation of Treg function will definitely provide us very promising tools to achieve clinical tolerance in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690028

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  10 in total

Review 1.  Regulatory T-cell therapy in transplantation: moving to the clinic.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

Review 2.  Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.

Authors:  Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

4.  Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses.

Authors:  A Anderson; C L Martens; R Hendrix; L L Stempora; W P Miller; K Hamby; M Russell; E Strobert; B R Blazar; T C Pearson; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2008-09-17       Impact factor: 8.086

Review 5.  Histone deacetylases as targets for treatment of multiple diseases.

Authors:  Jinhua Tang; Haidong Yan; Shougang Zhuang
Journal:  Clin Sci (Lond)       Date:  2013-06       Impact factor: 6.124

6.  Effects of nilotinib on regulatory T cells: the dose matters.

Authors:  Fei Fei; Yingzhe Yu; Anita Schmitt; Markus T Rojewski; Baoan Chen; Jochen Greiner; Marlies Götz; Donald Bunjes; Michael Schmitt
Journal:  Mol Cancer       Date:  2010-01-29       Impact factor: 27.401

Review 7.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

Review 8.  Epigenetic therapeutics in autoimmune disease.

Authors:  Moshe Szyf
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

9.  Regulation of immune responses by histone deacetylase inhibitors.

Authors:  Paul V Licciardi; Tom C Karagiannis
Journal:  ISRN Hematol       Date:  2012-03-18

Review 10.  Treatment of chronic kidney diseases with histone deacetylase inhibitors.

Authors:  Na Liu; Shougang Zhuang
Journal:  Front Physiol       Date:  2015-04-28       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.